CDMO241220C12500
- 0.10
- 0.000.00%
Avid Bioservices Newsroom
Vetter Strengthens Senior Management Team for Further Sustainable Growth
GBI Biomanufacturing Expands Capabilities With Automated Aseptic Fill-Finish for Drug Products
Avid Bioservices Gains as Holder Opposes $12.50 a Share Takeover
Punch and Assocs: Own About 4.5% of Avid Shares Outstanding
Punch and Assocs: Believe the Offer Materially Undervalues Avid
Express News | Punch and Associates: Intends to Vote Against Proposed Acquisition of Avid Bioservices by Gho Capital and Ampersand Capital
Punch and Associates Sends Letter to Board of Directors of Avid Bioservices, Inc.
Express News | Brock Pond Capital Partners: Urges Avid Bioservices to Remain Standalone Public Company Absent Improved Offer
Shareholder Alert: Ademi LLP Investigates Whether Avid Bioservices, Inc. Is Obtaining a Fair Price for Its Public Shareholders
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Avid Bioservices, Inc.
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Avid Biosciences Shares Are Trading Higher After the Company Announced It Agreed to Be Acquired by GHO Capital Partners and Ampersand in a $1.1 Billion Transaction. Also, RBC Capital Raised Its Price Target on the Stock From $12 to $12.5.
GHO and Ampersand Capital to Acquire Avid Bioservices
Avid Bioservices to Be Acquired in $1.1 Billion Deal
Here's Why Avid Bioservices (NASDAQ:CDMO) Can Afford Some Debt
RBC Capital Downgrades Avid Bioservices(CDMO.US) to Hold Rating, Raises Target Price to $12.5
William Blair Reiterates Market Perform on Avid Bioservices
Avid Bioservices Analyst Ratings
Express News | Avid Bioservices Inc : RBC Cuts to Sector Perform From Outperform